Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$6.86 CAD
Change Today +0.11 / 1.63%
Volume 49.8K
RX On Other Exchanges
As of 4:00 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

biosyent inc (RX) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/19/14 - C$12.82
52 Week Low
05/22/15 - C$6.63
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOSYENT INC (RX)

Related News

No related news articles were found.

biosyent inc (RX) Related Businessweek News

No Related Businessweek News Found

biosyent inc (RX) Details

BioSyent Inc., a life science company, engages in the marketing of pharmaceutical products in Canada. It is also involved in manufacturing and marketing non-chemical bio and health-friendly insecticides worldwide. The company markets FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; and FeraMAX Powder, an oral iron supplement. It also offers Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; endoscopies, proctoscopies, and rectoscopies; and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, BioSyent Inc. manufactures and markets Protect-It, a non-chemical, food-safe grain insecticide used as a preventative treatment against insect infestations in stored grains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 1947 and is headquartered in Toronto, Canada.

Founded in 1947

biosyent inc (RX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: C$225.7K
Chief Financial Officer and Vice President
Total Annual Compensation: C$136.6K
Vice President of Biosyent Pharma Inc
Total Annual Compensation: C$130.4K
Compensation as of Fiscal Year 2014.

biosyent inc (RX) Key Developments

BioSyent Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

BioSyent Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total sales of CAD 3,306,100, were 35% higher compared to CAD 2,448,101 in the corresponding prior year period. EBITDA was CAD 1,314,324 was 92% higher than CAD 686,283 in the corresponding prior year period. Net Income after Tax was CAD 962,712 or CAD 0.25 per diluted share increased by 88% over CAD 511,421 or CAD 0.15 per diluted share in the corresponding prior year period. Net Income before Tax was CAD 1,319,933 compared to CAD 687,672 in the corresponding prior year period.

BioSyent Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-05-2015 09:30 AM

BioSyent Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-05-2015 09:30 AM. Venue: Sheraton Centre Toronto Hotel (Corner of York and Queen St. West), Toronto, Ontario, M5H 3M9, Canada. Speakers: René C. Goehrum, Chairman, Chief Executive Officer and President.

BioSyent Inc., Annual General Meeting, Jun 12, 2015

BioSyent Inc., Annual General Meeting, Jun 12, 2015., at 09:00 US Eastern Standard Time. Location: the Sheraton Toronto Airport Hotel & Conference Centre. Agenda: To receive the audited financial statements for the fiscal year ended December 31, 2014, together with the auditors' report thereon; to elect directors for the ensuing year; to appoint auditors for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors; to consider and re-approve the company's ‘10% rolling’ incentive stock option plan in the form attached as Schedule ‘B’ to the accompanying information circular; and to transact such other business as may properly be transacted at such meeting or at any adjournment thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RX:CN C$6.86 CAD +0.11

RX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RX Industry Range
Price/Earnings 26.2x
Price/Sales 7.0x
Price/Book 9.9x
Price/Cash Flow 25.4x
TEV/Sales 6.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSYENT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at